Multi center randomized controlled clinical trial of Xiezhuo Tongluo Formula in the treatment of chronic kidney disease stage 3-4

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038512

Enrollment

Unknown

Registered

2020-09-23

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

Chinese medicine group:Xiezhuo Tongluo Formula + Western Medicine placebo

Benazepril group:Benazepril tablet + Chinese medicine placebo

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) It met the diagnostic criteria of CKD3-4 (2) Aged 18 to 75 years old and can sign the informed consent form independently (3) Blood pressure 100-160/60-100mmHg.

Exclusion criteria

Exclusion criteria: (1) Prepare for renal replacement therapy; (2) Immunosuppressive therapy were performed; (3) Patients with acute infection, serious primary diseases of heart, lung, brain, liver and hematopoietic system, diabetic ketoacidosis, malignant tumor, active tuberculosis and psychotic patients; (4) eGFR fluctuated more than 30% in three months; (5) Severe hyperkalemia (blood potassium>6.5mmol/L); (6) Allergy history to some components of the drug used; (7) Pregnant or during lactation; (8) Participated in other clinical studies.

Design outcomes

Primary

Measure	Time frame
eGFR;	—

Secondary

Measure	Time frame
ACR;Quality of life assessment;	—

Countries

China

Contacts

Public ContactTang Shuifu

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

tsf08@126.com+86 13609751775

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026